Project Grant R15HL179650
Award Date 8/15/26
Completion Date 4/30/29
Dollars Obligated $562K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waco, TX 76798, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $670,574 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to conduct research on diurnal adipose-heart lipid dynamics in the obesity paradox of heart failure. The research investigates why patients with higher body mass index experiencing heart failure exhibit better prognosis than those with lower BMI, despite obesity being a heart failure risk factor. The project tests the...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $158,892 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the impact of DNMT3A protein reduction on normal and clonal hematopoiesis. The research investigates mechanisms by which somatic DNMT3A mutations drive clonal hematopoiesis—the clonal expansion of mutated hematopoietic stem and progenitor cells—which accelerates with age and increases the risk of hematologic...
- The National Heart, Lung, and Blood Institute awarded William Marsh Rice University $638,014 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop CRISPR activation technologies that enhance mitochondrial biogenesis as a therapeutic strategy for heart failure following myocardial infarction. The project tests how CRISPR activation (CRISPRa) can stimulate endogenous PPARGC1A gene expression to increase mitochondrial capacity and cardiac function in...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,739 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to unravel the molecular mechanisms of immunotherapy-associated myocarditis. The research investigates how immune checkpoint inhibitors, which enhance anti-tumor immune responses in cancer treatment, trigger myocarditis—inflammation of the heart that carries mortality rates up to 50 percent. The project uses mouse models...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $799,920 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish mechanistic connections between chronic liver dysfunction and atrial arrhythmogenesis and to develop targeted therapeutic interventions. The project investigates the relationship between metabolic dysfunction-associated steatohepatitis (MASH) and atrial fibrillation (AF) risk. Research activities include...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $660,671 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop microbiome-based therapy for treatment-refractory graft-versus-host disease. The project investigates the role of ileal microbiota in graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. The research focuses on two mechanisms: insufficient suppression of alloreactive...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $132,452 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate genetic, metabolic, and sociodemographic factors underpinning pediatric out-of-hospital cardiac arrest. The research expands on prior population-based work evaluating more than 900 children with cardiac arrest. Baylor will evaluate oligogenic patterns in a large cohort of children with cardiac arrest,...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...